search
Back to results

Comparison of Two Biphasic Insulin Regimens

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Premixed Human Isophane Insulin Suspension + Human Insulin Injection
Premixed Insulin
Sponsored by
Aristotle University Of Thessaloniki
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring diabetes mellitus type 2, glycemic control, glycated albumin, continuous glucose monitoring, fructosamine, glycated hemoglobin, insulin, premixed human insulin, premixed insulin analog

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • regular attendees of Outpatient Clinic of the Diabetes Centre of the 1st Department of Internal Medicine of University Hospital in Thessaloniki Greece
  • The patients were on Premixed Human Insulin 30/70 twice daily with or without metformin
  • baseline HbA1c<7%

Exclusion Criteria:

  • the presence of type 1 Diabetes Mellitus
  • stage 4 Chronic Kidney Disease
  • use of antidiabetic medications other than insulin and metformin
  • major cardiovascular event during the last six months
  • acute illness and hospitalization during the last two weeks
  • pregnancy
  • absence of good metabolic control assessed with self-monitoring of blood glucose during the week before entering the study (>20% of the measurements <80mg/dl or >130mg/dl)
  • inability of the patients to understand the study procedures and sign the consent form

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Premixed Insulin

    Premixed insulin

    Arm Description

    Premixed Human Insulin

    Premixed Insulin Analog

    Outcomes

    Primary Outcome Measures

    Change in average blood glucose
    average blood glucose (mg/dl) from continuous glucose monitoring
    Glycated Albumin
    levels of glycated albumin (%) in serum
    Fructosamine
    levels of fructosamine (μmol/L) in serum

    Secondary Outcome Measures

    Daily Insulin requirements
    change in total daily dose of insulin (u)
    nocturnal average blood glucose
    change in nocturnal average blood glucose
    Time in range
    change in time in range (% and minutes) from continuous glucose monitoring
    time above 180
    change in time above 180 (% and minutes) from continuous glucose monitoring
    time below 70
    change in time below 70 (% and minutes) from continuous glucose monitoring

    Full Information

    First Posted
    January 23, 2021
    Last Updated
    January 23, 2021
    Sponsor
    Aristotle University Of Thessaloniki
    Collaborators
    University Hospital Tuebingen
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04726657
    Brief Title
    Comparison of Two Biphasic Insulin Regimens
    Official Title
    Comparison of Two Biphasic Insulin Regimens in Well-controlled Patients With the Use of Continuous Glucose Monitoring and New Glycemic Control Indices
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2021
    Overall Recruitment Status
    Completed
    Study Start Date
    January 18, 2016 (Actual)
    Primary Completion Date
    February 3, 2020 (Actual)
    Study Completion Date
    February 3, 2020 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Aristotle University Of Thessaloniki
    Collaborators
    University Hospital Tuebingen

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No

    5. Study Description

    Brief Summary
    Comparison of Two Biphasic Insulin Regimens in Well-controlled Patients With the Use of Continuous Glucose Monitoring and New Glycemic Control Indices
    Detailed Description
    A cross-over study of 36 well controlled people with type 2 Diabetes Mellitus who underwent 7-day Continuous Glucose Monitoring with Premixed Human Insulin 30/70 and subsequently with Biphasic Aspart 30.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetes Mellitus, Type 2
    Keywords
    diabetes mellitus type 2, glycemic control, glycated albumin, continuous glucose monitoring, fructosamine, glycated hemoglobin, insulin, premixed human insulin, premixed insulin analog

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Crossover Assignment
    Model Description
    Cross-over
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    36 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Premixed Insulin
    Arm Type
    Active Comparator
    Arm Description
    Premixed Human Insulin
    Arm Title
    Premixed insulin
    Arm Type
    Active Comparator
    Arm Description
    Premixed Insulin Analog
    Intervention Type
    Drug
    Intervention Name(s)
    Premixed Human Isophane Insulin Suspension + Human Insulin Injection
    Other Intervention Name(s)
    premixed human insulin
    Intervention Description
    premixed human insulin
    Intervention Type
    Drug
    Intervention Name(s)
    Premixed Insulin
    Other Intervention Name(s)
    Biphasic Aspart 30
    Intervention Description
    Premixed Insulin Analog Biphasic Aspart 30
    Primary Outcome Measure Information:
    Title
    Change in average blood glucose
    Description
    average blood glucose (mg/dl) from continuous glucose monitoring
    Time Frame
    7 days
    Title
    Glycated Albumin
    Description
    levels of glycated albumin (%) in serum
    Time Frame
    7 days
    Title
    Fructosamine
    Description
    levels of fructosamine (μmol/L) in serum
    Time Frame
    7 days
    Secondary Outcome Measure Information:
    Title
    Daily Insulin requirements
    Description
    change in total daily dose of insulin (u)
    Time Frame
    7 days
    Title
    nocturnal average blood glucose
    Description
    change in nocturnal average blood glucose
    Time Frame
    7 days
    Title
    Time in range
    Description
    change in time in range (% and minutes) from continuous glucose monitoring
    Time Frame
    7 days
    Title
    time above 180
    Description
    change in time above 180 (% and minutes) from continuous glucose monitoring
    Time Frame
    7 days
    Title
    time below 70
    Description
    change in time below 70 (% and minutes) from continuous glucose monitoring
    Time Frame
    7 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: regular attendees of Outpatient Clinic of the Diabetes Centre of the 1st Department of Internal Medicine of University Hospital in Thessaloniki Greece The patients were on Premixed Human Insulin 30/70 twice daily with or without metformin baseline HbA1c<7% Exclusion Criteria: the presence of type 1 Diabetes Mellitus stage 4 Chronic Kidney Disease use of antidiabetic medications other than insulin and metformin major cardiovascular event during the last six months acute illness and hospitalization during the last two weeks pregnancy absence of good metabolic control assessed with self-monitoring of blood glucose during the week before entering the study (>20% of the measurements <80mg/dl or >130mg/dl) inability of the patients to understand the study procedures and sign the consent form
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Triantafyllos Didangelos, Assoc. Prof.
    Organizational Affiliation
    AHEPA Hospital Aristotle University Of Thessaloniki
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    IPD Sharing Plan Description
    Upon request

    Learn more about this trial

    Comparison of Two Biphasic Insulin Regimens

    We'll reach out to this number within 24 hrs